Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C

Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C

Background/Purpose: The assessment of drug–drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC). This study aims to evaluate DDI before and during elbasvir/grazoprevir (EBR/GZR) treatment. Methods: CHC...

Full description

Bibliographic Details
Main Authors:	Chun-Jen Liu, Kuo-Chih Tseng, Ching-Chu Lo, I-Hao Tseng, Pin-Nan Cheng
Format:	Article
Language:	English
Published:	Elsevier 2020-05-01
Series:	Journal of the Formosan Medical Association
Subjects:	Drug–drug interaction Direct acting antivirals Elbasvir/grazoprevir
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664619306667

Similar Items

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
by: Eun Sun Jang, et al.
Published: (2021-03-01)

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection
by: Hussien Ahmed, et al.
Published: (2018-01-01)

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
by: Jin Chen, et al.
Published: (2020-01-01)

A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir
by: Kazuo Tarao, et al.
Published: (2017-11-01)

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
by: Li H, et al.
Published: (2020-02-01)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
by: Lin YC, et al.
Published: (2019-04-01)

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
by: Sulejmani N, et al.
Published: (2018-05-01)

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done
by: Susana Llerena, et al.
Published: (2019-01-01)

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
by: Ng X, et al.
Published: (2018-12-01)

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
by: Lina Weiss, et al.
Published: (2018-02-01)

Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V
by: N. V. Dunaeva, et al.
Published: (2020-03-01)

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
by: Gao LH, et al.
Published: (2021-01-01)

Spotlight on grazoprevir—elbasvir once-daily combination and its potential in the treatment of hepatitis C
by: Suraweera D, et al.
Published: (2016-06-01)

Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug–Drug Interactions with Antiviral Treatments for Hepatitis C
by: Andreas Hintz, et al.
Published: (2021-05-01)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019-01-01)

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
by: Zhdanov K, et al.
Published: (2020-04-01)

Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals
by: D. E. Valutite, et al.
Published: (2021-03-01)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
by: Youn Jae Lee, et al.
Published: (2019-12-01)

Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs
by: Francesco Giuseppe Foschi, et al.
Published: (2021-09-01)

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance
by: Lize Cuypers, et al.
Published: (2015-09-01)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
by: Hassan AM, et al.
Published: (2018-06-01)

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial
by: Jason Grebely, et al.
Published: (2020-06-01)

A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments
by: Andrew Radley, et al.
Published: (2019-10-01)

CSF3 Is a Potential Drug Target for the Treatment of COVID-19
by: Chao Fang, et al.
Published: (2021-01-01)

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients
by: Asmaa M. Elbrolosy, et al.
Published: (2021-03-01)

New drugs in the treatment of chronic hepatitis C
by: R. Jimenez Galan, et al.
Published: (2014-04-01)

The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis
by: Samah M. Alian, et al.
Published: (2020-09-01)

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance
by: Shaheen Khan, et al.
Published: (2020-06-01)

Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant
by: Lluís Castells, et al.
Published: (2017-01-01)

A modern view on the treatment of chronic hepatitis C in children and adolescents
by: G. V. Volynets
Published: (2020-01-01)

Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials
by: Yang YM, et al.
Published: (2017-04-01)

Grazoprevir/elbasvir combination therapy for HCV infection
by: Anaïs Vallet-Pichard, et al.
Published: (2017-01-01)

Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs
by: Martynas Ridziauskas, et al.
Published: (2021-02-01)

High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use
by: Akihiro Tamori, et al.
Published: (2020-10-01)

Lower Rates Of Naturally Occurring Resistance-Associated Substitutions (RASs) In Hepatitis C Virus (HCV)-Infected Chronic Kidney Disease (CKD) Patients Than In HCV-Infected Patients With Only Liver Disease
by: Gupta E, et al.
Published: (2019-11-01)

Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses
by: Rafaela S. Fernandes, et al.
Published: (2020-05-01)

Retrospective Evaluation on Patient Screening and Counseling Service on Direct-acting Antivirals Against Hepatitis C
by: Bob Ka Him Wong, et al.
Published: (2020-05-01)

“I want to get better, but…”: identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments
by: Trevor Goodyear, et al.
Published: (2021-03-01)

Clinical effect of elbasvir/grazoprevir in treatment of chronic hepatitis C in the real world
by: LIU Fang
Published: (2020-10-01)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
by: Morikawa K, et al.
Published: (2018-09-01)